Resources Repository
-
Resource PackPublication, Teaching Resource 2020Resource Pack: Cost-Effectiveness of SSB Excise Taxes
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior …
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior has been of increasing interest in the last decade as the evidence-base builds for the health and economic consequences of obesity, overweight, and unhealthy eating. The motivation for using fiscal instruments in nutrition policy is to make the unhealthy option less affordable and less economically attractive by increasing the price via a tax, and therefore reduce the incentive to consume…
Cost-Effectiveness Analysis | Health/Medicine | Oceania | North America | Health Outcomes | Evidence Synthesis | Mathematical Models | Microsimulation | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation | Business/Industry | Economics/Finance | Food/Agriculture | Government/Law | Latin America & Caribbean | Europe -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Health/Medicine | North America | Chronic Disease/Risk -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Cost-Effectiveness Analysis | Health/Medicine | North America | Mathematical Models | State-Transition | Chronic Disease/Risk | Clinical Care -
Resource PackWeb Portal, Teaching Resource 2023Resource Pack: Cost-Effectiveness of Screening and Treatment for Hypertension
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, …
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, and cost-effectiveness analysis. This resource pack provides examples of decision analyses and cost-effectiveness analyses for the management and treatment of hypertension, with a predominant focus on the U.S. Analyses are included that predate the 2017 American College of Cardiology/American Heart Association Clinical Practice Guidelines, along with more recent examples that followed release of the guidelines. Resources are also included that…
Cost-Effectiveness Analysis | Health/Medicine | North America | Preferences/Values | Test Performance | Decision Analysis | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology | Europe | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2022Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 …
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 billion in March 2021 for testing in schools. The study aimed to analyze the costs and benefits of different COVID-19 testing strategies, particularly focusing on full-time, in-person elementary and middle school education. Utilizing an updated agent-based network model, the study simulated transmission scenarios in schools, considering various testing strategies ranging from diagnostic testing (test-to-stay) to reduce symptom-based isolations, routine screening…
Cost-Effectiveness Analysis | Health/Medicine | North America | Test Performance | Mathematical Models | Infectious Diseases | Clinical Care | Science/Technology -
ArticlePublication 2022Hospital Closures amid COVID-19
The recent trend of hospital closures in the US has accelerated during the COVID-19 pandemic, …
The recent trend of hospital closures in the US has accelerated during the COVID-19 pandemic, as hospitals have experienced financial hardship from reduced patient volume and elective surgery cases, as well as the thin financial margins for treating patients with COVID-19. This trend of hospital closures is concerning for patients, healthcare providers, and policymakers. This current opinion piece describes the challenges caused by hospital closures and discusses what policymakers should know based on the existing…
Operations Research | Health/Medicine | North America | Health Systems -
ArticlePublication 2020Data-Driven Management of Post-Transplant Medications
Organ-transplanted patients typically receive high amounts of immunosuppressive drugs as a mechanism to reduce their …
Organ-transplanted patients typically receive high amounts of immunosuppressive drugs as a mechanism to reduce their risk of organ rejection. However, because of the diabetogenic effect of these drugs, this practice exposes them to a greater risk of new-onset diabetes after transplantation (NODAT), and hence, becoming insulin dependent. This study develops effective medication management strategies to address the common conundrum of balancing the risk of organ rejection versus that of NODAT. The article presents a robust…
Operations Research | Health/Medicine | North America | Mathematical Models | Chronic Disease/Risk -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Cost-Effectiveness Analysis | Health/Medicine | North America | Priority Setting/Ethics | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | Global -
ArticlePublication 2022Cost-Effectiveness of Masked Hypertension Screening and Treatment
The study assessed the health and economic outcomes of screening and treating masked hypertension in …
The study assessed the health and economic outcomes of screening and treating masked hypertension in U.S. adults using the Cardiovascular Disease (CVD) Policy Model, a microsimulation model. The model simulated 100,000 adults suspected of having masked hypertension (office blood pressure [BP] of 120–129/<80 mm Hg, not on antihypertensive medications, and without a history of CVD). Interventions included: usual care alone, usual care with ambulatory BP monitoring (ABPM), and usual care with home BP monitoring (HBPM).…
Cost-Effectiveness Analysis | Health/Medicine | North America | Microsimulation | Chronic Disease/Risk | Clinical Care